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Abstract
The hyaluronic acid receptor for endocytosis (HARE)/ Stabilin-2 
is the primary systemic scavenger receptor for hyaluronan (HA), 
the chondroitin sulfates (CS), dermatan sulfate (DS), and nongly-
cosaminoglycan (GAG) ligands such as acetylated low-density li-
poprotein (AcLDL), pro-collagen propeptides, and advanced gly-
cation end products. We recently discovered that HARE is also a 
systemic scavenger receptor for heparin (Hep) (Harris EN, Weigel 
JA, Weigel PH. 2008. The human hyaluronan receptor for endocyto-
sis [HARE/Stabilin-2] is a systemic clearance receptor for heparin. J 
Biol Chem. 283:17341–17350). Our goal was to map the binding sites 
of eight different ligands within HARE. We used biotinylated GAGs 
and radio-iodinated streptavidin or AcLDL to assess the binding 
activities of ligands directly or indirectly (by competition with un-
labeled ligands) in endocytosis assays using stable cell lines ex-
pressing the 315 or 190 kDa HA receptor for endocytosis (315- or 
190-HARE) isoforms, and ELISA-like assays, with purified recom-
binant soluble 190-HARE ecto-domain. For example, Hep binding 
to HARE was competed by DS, CS-E, AcLDL, and dextran sulfate, 
but not by other CS types, HA, dextran, or heparosan. 125I-AcLDL 
binding to HARE was partially competed by Hep and dextran sul-
fate, but not competed by HA. Two ligands, DS and CS-E, competed 
with both Hep and HA to some degree. Hep and HA binding or en-
docytosis is mutually inclusive; binding of these two GAGs occurs 
with functionally separate, noncompetitive, and apparently nonin-
teracting domains. Thus, HARE binds to HA and Hep simultane-
ously. Although the domain(s) responsible for Hep binding remains 
unknown, the Link domain was required for HARE binding to HA, 
CS-A, CS-C, and CS-D. These results enable us to outline, for the 
first time, a binding activity map for multiple ligands of HARE.
Keywords: chondroitin sulfate, endocytosis, glycosaminoglycan 
turnover, heparin, Stabilin-2
Introduction
Scavenger receptors are present in a variety of tissues, par-
ticularly the reticuloendothelial systems that clear the lymph 
and plasma of metabolic waste products and macromolecu-
lar debris. Currently, scavenger receptors are organized into 
five classes and one unclassified group (Yuasa and Watanabe 
2003). Scavenger receptors can be broadly expressed or tissue 
specific, e.g., ranging from MSR1, which is found in macro-
phages in diverse tissues (Ashkenas et al. 1993), to Macrosia-
lin/CD68, which is expressed only on macrophages found in 
the liver and peritoneum (Yoshida et al. 1998). The one com-
mon feature among scavenger receptors of the various classes 
is that they all bind low-density lipoprotein (LDL) and/or one 
or more naturally occurring LDL derivatives: acetylated LDL 
(AcLDL) and oxidized LDL (oxLDL). Most of these receptors 
also bind other classical polyanionic ligands such as maley-
lated bovine serum albumin (BSA), dextran sulfate, chondroi-
tin sulfate (CS), fucoidan, and polyribonucleotides (e.g., poly 
I, poly G). Although not all of these latter ligands occur natu-
rally, they all share features with natural analogs that facilitate 
high affinity and specific binding to their respective receptors 
(Krieger et al. 1993).
In this report, we characterize the ligand-binding profile 
of the hyaluronic acid (HA) receptor for endocytosis (HARE), 
also known as Stabilin-2/FEEL-2, which is a scavenger recep-
tor that is highly expressed in the sinusoidal, or noncontigu-
ous, endothelium of liver, lymph node, and spleen (Laurent 
and Fraser 1992). Fraser et al. (1983) first identified a scaven-
ger clearance activity for HA when they injected mice with 
14C-HA and found it sequestered in these organs. In addition, 
HARE is found in oviduct, corneal and lens epithelium, heart 
valve mesenchymal cells, ependymal cells lining ventricles in 
brain, and epithelial cells covering renal papillae (Falkowski 
et al. 2003). The rat receptor was identified, purified, and 
characterized first (Yannariello-Brown et al. 1997; Zhou et al. 
1999). Human HARE was later cloned and purified (Politz et 
al. 2002; Zhou et al. 2003), and then characterized in stable cell 
lines (Harris et al. 2004, 2007). The same protein was initially 
identified in the human genome database as a Stabilin-1 an-
alog of unknown function (Politz et al. 2002). Human HARE 
is a 2551-amino-acid, 315 kDa, type-1 transmembrane recep-
tor expressed on the cell surface and intracellular (e.g., endo-
cytic) compartments. Two HARE isoforms (not splice vari-
ants) of different mass (e.g., 190 kDa and 315 kDa in human) 
are found in native tissues (Zhou et al. 1999, 2003; Weigel et 
al. 2002). During biosynthesis and exocytosis in cells stably ex-
pressing full-length human HARE cDNA, a minor subset of 
the 315 kDa receptor pool is proteolytically cleaved to create 
the 190 kDa HARE, the C-terminal 1416 aa of the 315-HARE 
protein (Harris et al. 2007). Although the mechanism and bio-
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logical reasons for this protein processing are not yet known, 
both forms of the receptor are functional (Harris et al. 2004, 
2007) and occur in the same tissues.
HARE recognizes a host of different ligands, including HA 
(Yannariello-Brown et al. 1997; Politz et al. 2002), collagen N-
terminal pro-peptides (Hansen et al. 2005), advanced glyca-
tion endproducts (Tamura et al. 2003), AcLDL (Adachi and 
Tsujimoto 2002), CS A-E (Harris et al. 2004), phosphatidyl-
serine (Park et al. 2008), and αMβ2 integrin (Jung et al. 2007). 
We found recently that HARE is also a clearance receptor for 
heparin (Hep) (Harris et al. 2008). The receptor is composed 
of modular repeats of EGF, EGF-like, and Fasciclin domains. 
A defining feature of HARE is its Link domain, situated near 
the transmembrane domain, which closely resembles Link do-
mains in other HA-binding proteins such as TSG-6, CD44, and 
aggrecan (Day and Prestwich 2002).
Our goals in this study were to define which ligands com-
pete with one another, how the binding of one ligand affects 
the other, and the relative organization within HARE of bind-
ing sites for the different ligands. We primarily studied the 
190 kDa HA receptor for endocytosis (190-HARE), since it has 
higher expression as a cell surface receptor or secreted ecto-
domain than the 315 kDa HA receptor for endocytosis (315-
HARE). Both isoforms have very similar, if not identical, li-
gand-binding profiles.
Results
Antibody inhibition of Hep binding to HARE
hHARE, encoded by the STAB2 gene, specifically binds 
to HA and multiple CS types (Zhou et al. 2003; Harris et al. 
2004, 2007). We recently reported that HARE/Stab-2 is also 
the clearance or scavenger receptor for circulating Hep (Har-
ris et al. 2008). Although Hep binds to many proteins, includ-
ing coagulation factors, no specific receptor for Hep clearance 
had been identified. Specific Hep binding to purified recombi-
nant-secreted 190-HARE ecto-domain was blocked by a pAb 
against the purified s190-HARE protein (Figure 1A). At the 
maximum dose, ~70% of B-Hep binding to s190-HARE was 
blocked. In contrast, pre-immune Ab at the same concentra-
tion did not block Hep binding (not shown). Next, we evalu-
ated the internalization of B-Hep and B-HA by 190-HARE cells 
in the presence of a saturating amount (30 μg/mL) of rabbit 
anti-s190-HARE pAb or pre-immune IgG (Figure 1B). Anti-
s190-HARE, but not pre-immune, Ab inhibited the uptake 
of 125I-SA-B-Hep into 190-HARE cells by ~58% (gray bars), 
whereas 125I-SA-B-HA uptake was inhibited ~90% (black bars). 
In both cases, pre-immune IgG showed little or no inhibition. 
The differential inhibition of Hep versus HA binding by the 
same anti-HARE Ab indicates the possibility that these glycos-
aminoglycans (GAGs) bind to different sites.
HA and Hep bind to distinct and separate sites in 190-HARE
To determine if HA and Hep bind to the same, to overlap-
ping, or to different sites on 190-HARE, we used an ELISA-
like assay with B-GAGs and unlabeled GAGs as competitors 
(Figure 2A). We used a saturating concentration of B-HA to 
occupy all binding sites and saturate the HA response signal 
for this assay (black bar). In parallel, an amount of B-Hep that 
was not at saturation was used to produce a response signal 
lower than the HA signal (white bar). When these amounts of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B-HA and B-Hep were incubated together, they produced an 
additive signal (upper gray bar) that could be attenuated to 
the B-HA-alone signal in the presence of unlabeled Hep (lower 
gray bar). These results strongly indicate that Hep and HA do 
not bind within the same HARE-binding site and that, unlike 
TSG-6 which also binds both ligands separately, HARE can 
bind HA and Hep simultaneously.
To confirm this conclusion based on results from the 
ELISA-like assay, we performed similar experiments in cells 
stably expressing either the smaller 190-HARE isoform alone 
(Figure 2B) or the 315-HARE (Figure 2C); although the cDNA 
encodes full-length 315-HARE, these cells also make minor 
amounts of 190-HARE (Harris et al. 2007). The cellular accu-
mulation of 125I-SA-B-GAG in this assay monitors binding to 
HARE and receptor-mediated endocytosis. In these experi-
ments, the first set of wells contained only saturating amounts 
Figure 1. Anti-s190-HARE polyclonal Ab partially blocks both Hep 
and HA binding and endocytosis by HARE. (A) In ELISA-like assays, 
immobilized purified s190-HARE was incubated for 15 min with in-
creasing concentrations of anti-s190-HARE polyclonal IgG. Following 
three washes, increasing concentrations of anti-s190-HARE polyclonal 
IgG and 100 nM B-Hep mixtures were added to the wells and incu-
bated for 2 h at 37°C. After washing and detection with SA-AP, the 
A405 values were quantified and expressed as the mean ± SE (n = 4). 
(B) 190-HARE cells were treated as in Materials and methods and then 
incubated with 30 μg/mL pre-immune IgG or anti-s190-HARE im-
mune IgG for 15 min at 37°C, prior to the addition of 30 μg/mL pre-
immune or anti-s190-HARE IgG in combination with either 125I-SA-B-
Hep (gray bars) or 125I-SA-B-HA (black bars). The cells were allowed 
to endocytose GAG complexes for 4 h, washed with HBSS, and lysed 
with 0.3 N NaOH. Radioactivity and protein were quantified. The val-
ues are means ± SE (n = 3) expressed as the cell-associated specific 
CPM/μg protein.
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of either 125I-SA-B-Hep or 125I-SA-B-HA (Figure  2, B and C; 
black bars). In the second set of wells, we also added a 20-fold 
excess of unlabeled HA to the B-Hep mixture or unlabeled 
Hep to the B-HA mixture to determine if the binding of ei-
ther B-GAGs to membrane-bound HARE was cross-competed 
(Figure  2, B and C; dark gray bars). The results show that Hep 
and HA do not compete with each other for binding to either 
membrane-bound HARE isoforms.
Although one ligand might not bind to the other ligand-
binding site, occupancy of one site might alter (e.g., in an allo-
steric-like manner) the binding of the second ligand to its site. 
In the third set of wells (Figure  2, B and C; light gray bar), we 
added the 125I-SA-B-HA and 125I-SA-B-Hep mixtures together 
to determine if both GAGs could bind and be internalized 
noncompetitively, as in Figure  2A, or competitively (e.g., as 
in the case of TSG-6). The signals from the combined mixtures 
were additive (i.e., the sum of the signals obtained with each 
B-GAG alone), confirming that both GAGs bound to HARE in-
dependently and noncompetitively. A fourth set of wells con-
tained both 125I-SA-B-GAG mixtures plus a 20-fold excess con-
centration of one unlabeled GAG (Figure  2, B and C; white 
bars). Again, the unlabeled GAG only inhibited the binding of 
its corresponding B-GAG, without affecting the binding of the 
other B-GAG. All of the above results support the conclusion 
that the HA- and Hep-binding sites in HARE are separate and 
independent.
The hHARE Link domain is required for binding HA, but not 
Hep
To determine whether the Link domain is involved with 
HA binding, cells expressing the empty vector (EV), wild-
type 190-HARE, or 190-HARE lacking the Link domain 
(190-HARE(ΔLink)) were assessed for their ability to internal-
ize 125I-HA (Figure 3A). In cells without the Link domain, the 
binding and endocytosis of 125I-HA was ~90% less than in cells 
expressing wildtype 190-HARE. However, the small amount 
of HA internalization by 190-HARE(ΔLink) cells was signifi-
cantly higher than that for EV cells (p = 0.04; Student’s paired 
t-test); it is not known where this residual HA binding occurs 
within the 190-HARE(ΔLink) protein. Since many recombi-
nant Link domains bind HA, the results indicate that most of 
the HA binding to HARE is directly to the Link domain.
To determine if the Link domain is also necessary for 
endocytosis of Hep, cells expressing EV, 190-HARE, or 
190-HARE(ΔLink) were incubated with 125I-SA-B-Hep or 125I-
SA alone as a control (Figure 3B). Endocytosis of 125I-SA-B-
Hep complexes was not impaired in 190-HARE(ΔLink) cells, 
indicating that the HARE Link domain is not required for 
Hep binding. Surprisingly, 125I-SA-B-Hep uptake was actu-
ally greater in 190-HARE(ΔLink) cells than in 190-HARE cells. 
However, this increase was not due to a greater binding stoi-
chiometry of Hep with the receptor, but rather to increased ex-
pression of the 190-HARE(ΔLink) protein (Figure  3C). West-
ern analysis of cell lysates showed that 190-HARE(ΔLink) 
cells express ~50% more receptor than 190-HARE cells. The 
reason for increased expression is not known, but all three 
190-HARE(ΔLink) stable cell lines tested showed similar 
increases.
Sulfate groups are required for Hep binding with HARE
Since the sulfation of GAGs increases their negative charge 
and creates multiple types of disaccharide units, we assessed 
the ability of purified recombinant s190-HARE to bind B-Hep 
Figure 2. HA and Hep do not compete with each other and specifically 
and simultaneously bind to HARE. (A) In ELISA-like assays, immobi-
lized purified s190-HARE samples were incubated, without compet-
itor, with a saturating amount of B-HA (black bar) or a nonsaturat-
ing amount of B-Hep (white bar). These concentrations of B-HA and 
B-Hep were then incubated together with or without a 10-fold ex-
cess amount of unlabeled HA or Hep as competitor as indicated (gray 
bars). Assays were all performed simultaneously and bound B-GAG 
was detected using SA-alkaline phosphatase and p-nitrophenylphos-
phate. The A405 values are expressed as mean ± SE (n = 3). For endo-
cytosis assays, 190-HARE (B) and 315-HARE (C) cells were used to 
determine HA and Hep uptake and competition. 125I-SA-B-GAG com-
plexes were prepared and then incubated with cells as described in 
Materials and methods. Cells were incubated either with one labeled B-
GAG complex alone (black bars) and the other unlabeled GAG (dark 
gray bars), or with both labeled B-GAGs without (light gray bar) and 
with one unlabeled GAG as competitor (white bars). All sample wells 
contained equal amounts of 125I-SA. After 4 h at 37°C, the cells were 
washed with HBSS three times, lysed in NaOH, and radioactivity and 
protein were determined. Values are the mean ± SE (n = 3) expressed 
as the specific CPM/μg protein.
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in the presence of excess Hep or heparosan (Figure 4). Hep-
arosan, synthesized by Pasteurella multocida Heparosan Syn-
thase I, produces a 200–300 kDa Hep precursor polymer 
[(α1,4)GlcUA-(β1,4)GlcNAc] with no sulfate modifications 
(Sismey-Ragatz et al. 2007). A 10-fold excess of heparosan did 
not affect the binding of B-Hep to s190-HARE, whereas unla-
beled native Hep eliminated nearly all B-Hep binding. These 
data confirm that the sulfates on Hep play a crucial role for 
binding with HARE.
 
Dermatan sulfate (DS) partially inhibits HARE-mediated en-
docytosis of B-Hep
We next focused on whether any of the other GAGs com-
pete with Hep and HA for binding and endocytosis mediated 
by HARE. Since both Hep and DS contain iduronic acid and 
multiple sulfation sites, we tested if these two GAGs could 
interact with the same receptor-binding site (Figure 5). 190-
HARE and EV control cells were incubated with preformed 
125I-SA-B-Hep complexes with no competitors (filled circles 
and filled squares, respectively). Additionally, 190-HARE cells 
were incubated with preformed 125I-SA-B-Hep complexes in 
the presence of excess DS (filled triangles) or Hep (unfilled cir-
cles). Both cell lines were also incubated in parallel with 125I-
SA (plus biotin) alone to assess nonspecific internalization, 
which was ~5% of the signal with 125I-SA-B-Hep (not shown). 
Excess DS decreased the rate of 125I-SA-B-Hep internaliza-
tion by ~33%. EV cells incubated with 125I-SA-B-Hep alone 
Figure 3. The Link domain is required for HA binding, but not Hep 
binding. Human 190-HARE (●), 190-HARE(ΔLink) (■), and EV (▲) 
cells were grown and preincubated in a serum-free endocytosis me-
dium as noted in Materials and methods. (A) Cells were incubated with 
125I-HA alone or with a 50-fold excess of unlabeled HA and processed 
as in Figure  2 and Material and methods to assess total and nonspe-
cific endocytosis, respectively. The differences in uptake (total minus 
nonspecific) are expressed as the mean ± SE (n = 3) specific cell-as-
sociated CPM/μg cell lysate protein. The statistical difference in HA 
uptake between EV and 190-HARE(ΔLink) cells was significant, as 
measured by the unpaired Student’s t-test (p = 0.04), indicating that 
190-HARE(ΔLink) cells do internalize HA above EV control levels. 
(B) The same cells were incubated with 2.5 μg/mL 125I-SA-B-Hep (200 
nM) without or with a 10-fold excess of unlabeled Hep to assess non-
specific endocytosis. (C) Cell lysate proteins, as indicated, were sub-
jected to SDS–PAGE and Western blotting with anti-V5 Ab, using de-
tection by enhanced chemiluminescence, to determine the relative 
amounts of 190-HARE and 190-HARE(ΔLink) protein. Based on densi-
tometric analysis of bands using multiple film exposures, the amount 
of 190-HARE(ΔLink) protein was ~52% greater than wildtype protein 
in their respective cell lines.
Figure 4. Sulfation of Hep is required for binding with HARE. In 
ELISA-like assays with purified s190-HARE, 10 nM B-Hep without 
(black bar) or with (gray bars) 100 nM unlabeled competitor GAGs 
was incubated for 2 h at 37°C. The strips were washed, incubated with 
SA-AP, and bound B-Hep was detected with the development of p-ni-
trophenolphosphate over a 1 h period. All values are the mean ± SE (n 
= 3) absorbance at 405 nm. The error for the B-Hep plus Hep samples 
was very small; thus the error bars cannot be seen.
Figure 5. Endocytosis of Hep is partially competed by DS. Human 190-
HARE (●, ○, ▲) and EV (■) cells were grown and pre-incubated as de-
scribed in Materials and methods, and incubated with 200 nM 125I-SA-B-
Hep preformed complexes without (●, ■) or with 8 μM (40-fold excess) 
Hep (○) or DS (▲). At the indicated times, cells were washed, lysed, 
and radioactivity and protein were determined. Values are the mean ± 
SE (n = 3) specific cell-associated CPM/μg cell lysate protein. The aver-
age nonspecific internalization/binding of 125I-SA-biotin (~5% of total) 
was subtracted from the sample values shown. The symbols and lines 
for EV cells with 125I-SA-B-Hep (■) and 190-HARE cells with 125I-SA-B-
Hep plus unlabeled Hep (○) overlap.
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(squares) and 190-HARE cells incubated with 125I-SA-B-Hep 
in the presence of excess unlabeled Hep (open circles) showed 
essentially no specific internalization.
DS competes with both HA and Hep, which do not compete 
with each other
Next, we used the ELISA-like assay to examine the relation-
ship among HA-, Hep-, and DS-binding sites on the purified 
s190-HARE. First, we tested the binding of B-HA in the pres-
ence of unlabeled HA, DS, or Hep (Figure 6; black bars). As ex-
pected, HA competed effectively (68%), but DS or Hep did not. 
Second, we tested the binding of B-Hep to s190-HARE in the 
presence of unlabeled HA or DS (Figure  6; gray bars). B-Hep 
binding was reduced by Hep (>98%) or DS (71%), but not by 
HA. The lack of cross-competition between HA and Hep bind-
ing to HARE further supports the conclusion that they bind to 
separate and distinct sites. Third, we tested B-DS binding to 
s190-HARE in the presence of unlabeled Hep or DS (Figure 6; 
white bars). B-DS binding was well competed by DS (>97%) and 
Hep (>99%) but only partially blocked by HA (30%). The results 
indicate that DS binds within or near the Hep-binding site and 
also to a lesser degree with the HA-binding site. A similar result 
was also obtained with 190-HARE or 315-HARE cells incubated 
with 125I-HA and excess DS; a small, but significant, amount of 
125I-HA uptake was competed by DS (Harris et al. 2007).
Dextran sulfate (Dx-S) and CS-E inhibit Hep binding to puri-
fied s190-HARE
Dx-S is a synthetic polyanionic polysaccharide, whose de-
gree of sulfation can be varied, and that can mimic some of 
the sulfation patterns and properties of a GAG, including Hep. 
In ELISA-like assays with purified s190-HARE, B-Hep binding 
was progressively inhibited by increasing concentrations of 
Dx-S (Figure 7A), indicating that Dx-S competes with Hep for 
a common s190-HARE-binding site. In fact, for equivalent mo-
lar amounts, Dx-S was a better competitor for B-Hep binding 
than unlabeled Hep. This suggests that the right sulfation pat-
tern needed for HARE binding occurs more frequently in Dx-S 
than in Hep, even though the mass of Dx-S is approximately 
half of the Hep mass.
We used ELISA-like assays to assess whether CSs A–E, 
chondroitin (Chon), or heparan sulfate (HS) can also com-
pete for the binding of B-Hep to s190-HARE (Figure  7B). The 
only GAG that significantly decreased B-Hep binding, other 
than Hep and DS (CS-B), was CS-E (chondroitin 4,6-disulfate); 
no significant competition was seen with Chon, CS-A, CS-C, 
CS-D, HS, or HA. These results indicate that negative charge 
density is not the only, or even the key, factor involved with 
Hep binding, but rather the spatial organization and orienta-
tion of charge groups likely determines how well the mole-
cule fits into the Hep-binding site(s) of HARE. We also used 
these ELISA-like and cell-based endocytosis assays to deter-
mine if keratan sulfate (KS) affects B-Hep binding and found 
that KS, like HS and HA, does not compete for B-Hep binding 
to HARE (not shown).
AcLDL endocytosis by 190-HARE cells is competed by Hep 
and DS
We compared the ability of EV and 190-HARE cells to en-
docytose 125I-AcLDL and found that the level of nonspecific 
binding with excess AcLDL was moderately low (equivalent 
in both cell lines and ~25% of total HARE-mediated binding). 
Nonspecific endocytosis was subtracted from the total endo-
cytosis to obtain 190-HARE-mediated specific endocytosis of 
125I-AcLDL (Figure  8, black bar). In the same experiment, we 
Figure 6. DS competes with both HA and Hep, which do not compete 
with each other, for binding to HARE. In ELISA-like assays with pu-
rified s190-HARE, B-HA (black bars), B-Hep (gray bars), and B-DS 
(white bars) were incubated alone or with a 10-fold excess of the indi-
cated unlabeled GAG for 2 h at 37°C. Results within each of the three 
datasets were normalized to 100% for the B-GAG alone. Bound B-
GAG was detected and quantified using SA-AP. Colorimetric reaction 
values are the mean ± SE (n = 3) A405.
Figure 7. Heparin binding to HARE is competed by Dx-S, DS, and 
CS-E. B-Hep was incubated in ELISA-like assays with purified s190-
HARE, with no addition (black bars) or with the indicated excess un-
labeled GAG (gray bars) in two separate experiments. Bound B-Hep 
was detected as in Figure  4; color development values are the mean ± 
SE (n = 3) A405. (A) B-Hep binding was determined in the presence of 
excess Hep or increasing concentrations of Dx-S. (B) B-Hep binding 
was determined in the presence of a 10-fold excess of unlabeled Hep 
or eight other individual GAGs.
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assessed the competitive abilities of unlabeled Hep, HS, DS, 
Dx, and Dx-S (Figure  8, gray bars). Hep and Dx-S, which com-
pete with each other as noted above, inhibited 125I-AcLDL en-
docytosis by 60% and 95%, respectively, whereas DS reduced 
125I-AcLDL internalization by only 20%. HS and nonsulfated 
dextran had no effect on 125I-AcLDL binding and endocytosis 
by HARE. Thus, although HS and Hep share many similari-
ties, the results confirm that HS does not bind to HARE at the 
HA-binding site or the Hep-binding site, which is also shared 
by Dx-S and AcLDL.
Endocytosis of AcLDL by 190-HARE cells is only partially 
competed by Hep and DS
Earlier results showed that DS blocks HA uptake only par-
tially by 190-HARE cells (Harris et al. 2004, 2007). Based on 
results in Figure  7 and Figure 8, DS also competed for Hep 
and AcLDL binding, with different apparent affinities for 
HARE. Since DS and Hep bind to the same region of HARE, 
we tested how increasing concentrations of each affected the 
binding and endocytosis of a fixed amount of 125I-AcLDL by 
190-HARE cells (Figure  9). Both Hep and DS displayed simi-
lar dose-response inhibition curves that saturated at ~0.5 μM 
and resulted in only partial displacement of 125I-AcLDL. Maxi-
mum inhibition by DS and Hep plateaued at 25% and 50%, re-
spectively, although the apparent Ki values were similar at ~50 
nM. These results indicate that the three ligands (DS, Hep, and 
AcLDL) have both common overlapping and unique sites of 
interaction with HARE.
AcLDL blocks endocytosis of Hep, but not HA, by 190-HARE 
cells
Endocytosis of 125I-SA complexes with B-HA or B-Hep 
was evaluated in cells expressing either 190-HARE (Figure 
10, white bars) or 190-HARE(ΔLink) (Figure  10, gray bars) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
with or without unlabeled AcLDL. In 190-HARE cells, AcLDL 
did not decrease B-HA uptake, but reduced B-Hep uptake 
by >50%. Predictably, AcLDL also decreased B-Hep uptake 
in 190-HARE(ΔLink) cells. Additionally, the small amount of 
B-HA accumulation by 190-HARE(ΔLink) cells was not af-
fected by AcLDL. We conclude from this experiment that 
AcLDL binds within the Hep-binding domain, but not the 
HA-binding Link domain. Furthermore, the residual HA-
binding site in the 190-HARE(ΔLink) mutant receptor also ap-
pears to be distinct from the AcLDL-binding site.
Discussion
Recently, we showed that HARE specifically binds with 
Hep (Harris et al. 2008). It is likely that HARE is the primary 
scavenger receptor for removing Hep from blood and lymph 
fluid. In this report, we show for the first time that HARE can 
Figure 8. 125I-AcLDL endocytosis is competed by Hep, DS, or Dx-S. 
190-HARE (black bar) and EV (not shown) cells were incubated as 
in Figure  1B with an endocytosis medium containing 2 μg/mL 125I-
AcLDL for 4 h at 37°C. To account for nonspecific binding and endo-
cytosis of 125I-AcLDL, the average cell-associated radioactivity of EV 
cells was subtracted from the 190-HARE cell values. To test the com-
petition by other GAGs for 125I-AcLDL binding and endocytosis, 190-
HARE cells were also incubated with excess (4 μM) unlabeled GAG as 
indicated. The mean ± SE (n = 3) values for the specific cell-associated 
CPM/μg cell lysate protein were determined as in Figure  1B and Mate-
rials and methods.
Figure 9. Hep competes more than DS for 125I-AcLDL. 190-HARE cells 
were prepared for endocytosis assays as in Figure  1B. (A) Hep or DS 
was added, to the indicated concentration, to cells in the endocytosis 
medium containing 2 μg/mL 125I-AcLDL. After 3 h at 37°C, the cells 
were washed, lysed, and radioactivity and protein were determined. 
Values are the mean ± SE (n = 3) cell-associated CPM/μg cell lysate 
protein.
Figure 10. AcLDL competes for Hep, but not HA, binding and endo-
cytosis by both 190-HARE and 190-HARE(ΔLink) cells. 190-HARE 
(white bars) and 190-HARE(ΔLink) (gray bars) cells were prepared for 
endocytosis assay as described in Figure  1B and Materials and methods. 
Preformed complexes (100 nM) of 125I-SA-B-HA (solid bars) or 125I-SA-
B-Hep (cross-hatched bars) were prepared and added to cells with or 
without 50 μg/mL AcLDL, as indicated. After 4 h at 37°C, cell-associ-
ated CPM/μg cell lysate protein values (mean ± SE; n = 3) were mea-
sured as noted in Figure  1B and Materials and methods.
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specifically and simultaneously bind to both Hep and HA, 
which do not compete with each other. Five other new find-
ings are (i) HARE binds DS predominantly within part of the 
Hep-binding site(s) and only to a lesser extent within the HA-
binding sites; (ii) AcLDL specifically binds HARE and binding 
is competed robustly by Hep or Dx-S, partially by DS, but not 
at all by HA; (iii) at least 90% of the HA-binding activity is due 
to the HARE Link domain and the remaining ~10% binds to 
HARE at an unknown site; (iv) HARE lacking the HA-binding 
Link domain still binds normally with AcLDL or Hep; and (v) 
only DS and CS-E bind within parts of both the Hep- and HA-
binding sites. Previous results showed that CS-A, CS-C, and 
CS-D all bind within the HA-binding site of HARE (Harris et 
al. 2004, 2007), and the present results confirm that the Link 
domain is the major HA-binding site. The Link domain is also 
required to bind these CS types (data not shown).
Thus, our results show that HARE/Stabilin-2 specifically 
binds with AcLDL and seven different GAGs (HA, Hep, CS-
A, CS-C, CS-D, CS-E, and DS), as well as the synthetic glycan, 
Dx-S, at two primary independent sites. Based on experiments 
outlined in this and previous reports, our current model for 
the organization of these multiple ligand-binding sites illus-
trates that the HA-binding (Link) domain is completely sep-
arate from the Hep- and AcLDL-binding domain (Figure  11). 
Hep and HA bind to mutually inclusive sites (the two largest 
nonoverlapping circles, Figure  11) within the 190-HARE iso-
form (Figures 1B and 2). Although it was assumed that the 
Link domain is the primary HA-binding site, this is the first re-
port to demonstrate this experimentally (Figure  3A). Figure  3B 
also confirms that the Link domain is not involved with Hep 
binding, since cells expressing 190-HARE(ΔLink) internalize 
Hep. DS competes with the binding of both Hep (Figures 5, 
6, and  7B) and HA (Figure 6; Harris et al. 2004, 2007) although 
there is a higher level of competition with Hep than with HA 
(Figure  6). CS-E binding to HARE is competed by both Hep 
(Figure  7B) and HA (Harris et al. 2004) to the same extent; thus 
bound CS-E may span both binding sites equally. It is also 
possible that DS or CS-E bind independently, and with differ-
ent affinities, to parts of the Hep and HA binding sites. CS-A, 
CS-C, and CS-D all compete only with HA (Harris et al. 2004) 
and not Hep (Figure 7B). Others reported that HARE is a scav-
enger for AcLDL (Adachi and Tsujimoto 2002; Tamura et al. 
2003). In our direct labeling and competition studies, AcLDL 
competed with Hep (Figures 8 and  10), DS (Figures  8 and  9), 
but not with HA (Figure 10). AcLDL binding was also com-
peted with Dx-S (Figure  8), a competitor for Hep binding (Fig-
ure  7A), but not with HS (Figure  8). A portion of the AcLDL-
binding site lies outside of both the Hep and HA sites (Figure 
9) (Figure 11, circles).
The in silico structure of the HARE/Stabilin-2 Link do-
main is predicted based on the structures of other Link-con-
taining proteins (Blundell et al. 2005). Link domains contain a 
groove for the HA strand to slip into and interact with three 
Tyr (aromatic) and two Lys/Arg (basic) residues. The Hep-
binding site of HARE is still unknown and may be situated 
within the EGF domains of the protein. It does not appear to 
be located within a separate binding groove of the Link do-
main, as seen with TSG-6 (Mahoney et al. 2005). In TSG-6, 
HA and Hep or HS bind within the Link domain in separate 
binding grooves. When Hep or HS bind, there is a conforma-
tional change in the protein that prevents HA from binding 
and likewise, if HA binds then the Hep- or HS-binding site 
is inactive. Thus, HA and Hep both cannot bind simultane-
ously to TSG-6 (Mahoney et al. 2005). In contrast, despite the 
high homology (48% identical and 64% similar) between the 
TSG-6 and HARE Link domains, we do not see a contribution 
to Hep-binding activity by the HARE Link domain. In space-
filling models of the TSG-6 Link domain, the Hep saccharide 
chain is positioned to interact with basic residues at positions 
34, 54, and 56 (Link domain numbering); of these residues, 
only R56 is present in the Link domain of HARE. Other amino 
acids possibly involved in electrostatic interactions with the 
sulfate groups of Hep (Mahoney et al. 2005) are present in 
Link domains of both HARE (R20, K41, K72, K84) and TSG-6 
(K20, K41, K72, R84).
The HARE Link domain functions differently than that of 
TSG-6, since both HA and Hep bind with HARE simultane-
ously, and 190-HARE(ΔLink) binds with Hep at least as well 
as the wildtype receptor. Another difference between the 
HARE and TSG-6 Link domains is that both Hep and HS bind 
to the same site on TSG-6 Link, but HARE Link binds only HA 
and not HS (Figure 7B; Mahoney et al. 2005). Direct binding 
assays found no HS-binding activity in purified s190-HARE 
or membrane-bound 190-HARE. One difference between Hep 
and HS is that Hep is more highly sulfated. Hep sulfation oc-
curs almost entirely along the sugar backbone in contrast to 
HS, which contains islands of high sulfation between long 
stretches of low sulfation (Bame 2001). Compared to HA, Hep 
contains IdoA(2S)-(α1,4)-GlcNS(6S) in greater abundance than 
IdoA-(α1,4)-GlcNS(6S) and IdoA(2S)-(α1,4)GlcNS, which helps 
to give Hep a higher sulfation density. GlcNS(6S) residues of 
Hep also promote more of the rare 3-O sulfation of GlcNS(6S), 
to form GlcNS(3S,6S), than in HS (Rabenstein 2002). In con-
trast, HS contains more GlcNAc than GlcNS, rarely any 3-O 
Figure 11. Relative organization of ligand-binding sites of the 190-
HARE ecto-domain. The upper schematic binding site model is based 
on data from this and other studies using ELISA-like or endocytosis 
assays with different HARE constructs, cell lines, and combinations 
of the eight ligands shown. The relative size of the circles/ovals ap-
proximates the relative binding affinity of a ligand and placement of 
shape corresponds to relative location along the 190-HARE protein. 
Ovals indicate binding regions that overlap with the two main bind-
ing sites for HA and Hep. The lower linear domain model of the 190-
HARE protein shows that the Link domain (dark gray) is required, or 
partially used, for binding to six of the eight ligands. We do not yet 
know the locations of the binding sites for Hep, AcLDL, CS-E, and DS 
within the large region upstream of the Link domain.
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sulfate, and the ratio per disaccaride of HS O-sulfate to Hep O-
/N-sulfate is 0.2–0.7:2.4. We assume that the specific binding 
of HARE to Hep, but not HS, involves some of these structural 
differences between HS and Hep sulfation.
The full-length HARE/Stabilin-2 receptor contains four 
Cys-rich EGF clusters and seven Fasciclin domains. The 190-
HARE encoding region contains the two C-terminal EGF clus-
ters and four of the Fasciclin domains. Since both the full-
length 315 kDa and 190 kDa HARE receptor ecto-domains 
bind Hep to the same extent and the same affinity (Harris et 
al. 2008), the Hep-binding site(s) must be contained within the 
190-HARE-encoding region. Fasciclin domains may not con-
tribute to the Hep-binding sites, since the Fasciclin domain is 
involved with binding αMβ2 integrins (Jung et al. 2007). The 
integrin-binding Fascilin domains of the receptor may serve a 
general adhesive function, since cells with high expression of 
surface HARE exhibit greater cell–cell and cell–substratum ad-
hesion than EV cells (not shown).
Heparosan, which is the Hep precursor polymer and lacks 
negatively charged sulfate groups or epimerized uronic acids, 
does not bind with HARE. Likewise, Dx-S competes with Hep 
for HARE binding, whereas the unsulfated dextran does not. 
On the other hand, charged residues alone cannot account for 
all the binding specificity or activity of HARE for Hep, Dx-S, 
and DS polymers. If that were the case, then all of the CS spe-
cies would interfere with Hep binding. CS-A and CS-C have 
one sulfate (two negative charges) per disaccharide unit and 
CS-D and CS-E have two sulfates (three negative charges) per 
disaccharide unit. Based on the results presented here and 
other supporting data (not shown), only DS and CS-E com-
peted for Hep binding to HARE; CS-A, CS-C, and CS-D did 
not compete. The different CS types are all highly negatively 
charged and if sulfate group density were solely responsible 
for binding to HARE, then most or all the CS species should 
inhibit Hep binding to various degrees.
All of the classified scavenger receptors bind one or more 
forms of LDL such as AcLDL (Yuasa and Watanabe 2003). 
Other groups have used either 125I-AcLDL in direct bind-
ing assays with cells expressing Stabilin-2 (i.e., both isoforms) 
(Tamura et al. 2003) or AcLDL in indirect assays as a compet-
itor for 125I-AGE-BSA binding (Adachi and Tsujimoto 2002). 
This is the first report to show the direct binding of 125I-AcLDL 
by the 190-HARE and to assess competition with unlabeled 
GAGs. We found in this study that 125I-AcLDL endocytosis by 
cells expressing 190-HARE was completely inhibited by Dx-S 
and partially inhibited by Hep and DS (Figure 8). The relative 
binding affinities of two ligands for the same site will deter-
mine the equilibrium distribution of both ligands. For exam-
ple, in Figure 6, B-HA was not competed by excess unlabeled 
DS, but some of the B-DS was competed by HA. This appar-
ent discrepancy could be explained because HA binding to the 
HA site has a higher affinity (KD ~18 nM) than DS binding to 
the HA site, or there is more than one DS-binding site along 
the receptor. A plateau effect in dose inhibition curves may in-
dicate that one ligand interacts with only part of the binding 
site(s) of the other, which is thus still able to bind to HARE 
with good affinity. All of our data indicate that the AcLDL-
binding site overlaps the Hep/DS sites and does not include 
or overlap with the HA-binding site.
The findings in this report may be very significant physi-
ologically for several reasons. The simultaneous endocyto-
sis of HA/CS and Hep/Hep-like proteoglycans is likely to be 
very important because these GAGs are continuously shed 
from extracellular matrixes (ECMs) in tissues throughout the 
body. That HA/CS and Hep can be simultaneously cleared 
from circulating lymph or blood by the same receptor indi-
cates a strong biological “need” or evolutionary pressure to 
have an effective mechanism that removes multiple classes 
of ECM molecules in a coordinated way. We recently found 
that HARE mediates the activation of intracellular ERK-sig-
naling pathways in response to HA binding (Kyosseva et al. 
2008). Thus, an additional exciting possibility is that in per-
forming its function of clearing multiple GAGs, HARE may 
also provide a mechanism by which the body senses, evalu-
ates, and responds to ECM turnover and degradation. Nor-
mally, proteoglycans, such as aggrecan, are partially degraded 
and replaced at a slow rate, but turn over much faster during 
inflammation and tissue remodeling. The large initial degra-
dation products can be internalized by local cells or profes-
sional phagocytes in a tissue or flow/perfuse into the general 
systemic circulation, from which they are removed by HARE. 
HARE is the primary clearance receptor for CS proteoglycan 
fragments and Hep-bound proteins in the lymph and circula-
tory fluids, which constitute the systemic circulation.
Thus, HARE is an efficient scavenger for most of the GAGs, 
even those that are rare (e.g., CS-E; Ten Dam et al. 2007) and 
transiently produced in pathological situations. HA, CS, and 
Hep GAG chains may also serve as “handles” that bind with 
HARE and indirectly enable the clearance of a multitude of 
different growth factors, GAG-binding proteins, and other 
ECM proteins that are in complex with these GAGs. This 
“piggy-back” clearance role for HARE would allow an effi-
cient removal of the waste proteoglycan-associated material 
generated during infection, inflammation, development, tissue 
remodeling, and disease processes in distal tissues (Harris and 
Weigel 2008).
Materials and methods
Reagents and buffers
Purified unfractionated Hep (UFH) was from Celsus (Cin-
cinnati, OH) and Sigma (St. Louis, MO), weight-average 
mass = 19 kDa. HA from Genzyme (Framingham, MA) was 
acid hydrolyzed under mild conditions (Raja et al. 1988), fol-
lowed by neutralization to obtain a weight-average mass of 
100 kDa. CS-A was from CalBiochem (La Jolla, CA) and DS, 
CS-C, CS-D, CS-E, and HS were from Seikagaku Corp. (To-
kyo, Japan). All GAG preparations were analyzed by size 
exclusion chromatography/multiangle laser light scatter-
ing to determine concentration and weight-average poly-
mer mass (Baggenstoss and Weigel 2006). Biotinylated hepa-
rin and HA (B-Hep, B-HA) were prepared using the method 
of Yu and Toole (1995), with slight modifications (Harris et 
al. 2007). AcLDL was from AbD Serotec (Raleigh, NC). Flp-
In 293 cells, culture medium, transfection reagents, and plas-
mids were from Invitrogen/Gibco (Carlsbad, CA). pfu ultra 
HF was from Stratagene (La Jolla, CA). Classic Blue BX film 
was from MidSci (St. Louis, MO). Streptavidin (SA), 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide HCl (EDC), bio-
tin-LC-hydrazide, sulfo-NHS-SS-biotin, SnakeSkin dialysis 
tubing (MWCO 3500) and chemiluminescence reagents, Lu-
minol and Peroxide solutions, were from Pierce (Rockford, 
IL). Polysorp well strips were from Nunc (Roskilde, Den-
mark) and p-nitrophenylphosphate was from Kirkegaard & 
646 har r i s & We ig el i n Gl y c obi o l o G y  18 (2008) 
Perry Laboratories, Inc. (Gaithersburg, MD). 125I (100 mCi/
mL; specific activity of >0.6 TBq/mg) in NaOH and Sepha-
rose 6 Fast Flow (Nickel NTA) resin were from GE/Amer-
sham Biosciences (Piscataway, NJ). 125I-SA and 125I-HA were 
prepared as described previously (Weigel 1980; McGary et al. 
2003). Concentrator/desalting Centricon devices were pur-
chased from Amicon (Bedford, MA). Protein A/G agarose 
resin was from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA). Tris-buffered saline containing Tween-20 (TBST) con-
tains 20 mM Tris–HCl, pH 7.0, 150 mM NaCl, and 0.1% (v/v) 
Tween-20. Coating buffer for ELISA assays contains 15 mM 
Na2CO3, 36 mM NaHCO3, pH 9.5. Blocking buffer is TBST 
with 2% (w/v) BSA. Endocytosis medium is DMEM contain-
ing 0.05% BSA. Hank’s balanced salts solution (HBSS) con-
tains 5 mM KCl, 0.4 mM KH2PO4, pH 7.2, 0.8 mM MgSO4, 
137 mM NaCl, 0.3 mM Na2HPO4, 5.5 mM Glucose, 1.26 mM 
CaCl2, 0.5 mM MgCl2, and 28 μM phenol red. SA-alkaline 
phosphatase conjugate and other salts and reagents were 
from Sigma (St. Louis, MO).
Preparation of s190-, s315-, and 190-HARE(ΔLink) constructs
cDNA constructs encoding the secreted ecto-domains of 
the 315 kDa and 190 kDa human HARE were produced by 
the previous method in which the transmembrane and cy-
toplasmic domains were deleted, while retaining the C-ter-
minal V5 and His6 epitope tags (Harris et al. 2007). A single 
primer (5′-GTGACCTTGACCCACACTGGATCCG- AAGG-
TAAGCCTATC-3′) was used in individual mutagenic re-
actions with the wildtype HARE cDNAs (315-HARE in 
pcDNA5/FRT/V5/His, 190-HARE in pSecTag/FRT/V5/
His) in an Ericomp thermocycler (18 cycles: 94°C, 30 s; 
63°C, 30 s; 71°C, 1 min/plasmid kb) using pfu ultra HF. 
To make the 190-HARE(ΔLink) construct, a single primer 
(5′-CCACTTCCAGGATACCACTGTTCGGATGAAAGATGT 
GAACTGCACC-3′) was used with the 190-HARE wildtype 
template to delete the Link domain (18 cycles: 94°C, 30 s; 
62°C, 30 s; 71°C, 1 min/plasmid kb). After these reactions, 
the plasmids were ethanol-precipitated and resuspended in 
17 μL H2O, 2 μL NEB4 buffer, and 2.5 U of DpnI to cut tem-
plate plasmids, while retaining intact mutant plasmids. Af-
ter overnight incubation at 37°C, the digestion mixtures were 
heated to 95°C for 10 min and immediately transformed into 
TOP10 supercompetent Escherichia coli cells. Bacterial colo-
nies were screened by a miniprep procedure, PCR, and se-
quencing to confirm the desired mutation. Plasmids contain-
ing correct mutations, open reading frames, and promoter 
regions were used to make stable cell lines as described in 
Harris et al. (2004, 2007).
Purification of s190-HARE
s190-HARE was purified from the conditioned cell cul-
ture medium by immobilized Ni-chelate affinity chroma-
tography. The media (250 mL) were prepared by the addi-
tion of 250 mM NaCl, 10 mM imidazole, and 10% glycerol 
to the indicated final concentration. Two milliliters of a 50% 
slurry of Ni-chelate resin was added, the mixture was incu-
bated overnight at room temperature with slow rotation, and 
then passed through a 20 mL column to capture the resin. 
The resin was washed three times with one bed volume of 
500 mM NaCl, 20 mM Na2HPO4, and 10 mM imidazole, pH 
7.2. The s190-HARE protein was eluted with four successive 
1 mL portions of the same buffer containing 400 mM imidaz-
ole. For efficient elution of s190-HARE, the first portion was 
added, the resin was stirred to create a suspension, and after 
incubation at 22°C for 10 min, the column was then eluted. 
The next three 1 mL volumes were successively added, in-
cubated for 10 min without mixing, and then eluted. This 
procedure recovered >90% of the protein associated with 
the resin. The four eluted fractions were pooled and concen-
trated to ~0.2 mL using a 30 MWCO concentrator. The s190-
HARE preparations were ~10–20% pure, since some serum 
proteins in the media also adhered to the resin in a Ni-depen-
dent fashion.
To further purify the s190-HARE protein for ELISA assays, 
the concentrated semi-pure s190-HARE was fractionated by 
5% SDS–PAGE. The s190-HARE band, which separated dis-
tinctly from other bands, was identified in the gel by neg-
ative staining (using 4% CuCl2 in water) and excised with a 
clean razor blade. The gel was minced to smaller pieces, which 
were destained with 0.25 M EDTA, 0.15 M Tris–HCl, pH 7.6, 
placed in a SnakeSkin dialysis bag with 5–10 mL 185 mM gly-
cine, 2.5 mM SDS, and 25 mM Tris–HCl, pH 8.3, and electroe-
luted using a horizontal gel box for 16 h at 35 V, 4°C. The so-
lution within the dialysis bag was collected, concentrated, 
and washed as above with phosphate-buffered saline (PBS), 
and re-concentrated to 0.25 mL. Purity (~99%) was verified 
by SDS–PAGE, silver staining, and Western blot analysis. Pro-
tein concentration was determined by the bicinchoninic acid 
method (Smith et al. 1985).
ELISA-like assay
The purified s190-HARE protein was diluted in the coating 
buffer at 1.0 μg/mL and 200 μL was added to each Polysorp 
well, sealed with Scotch tape, and incubated at 22oC for 16 h. 
All the following steps were performed at 37°C. After coat-
ing, the Polysorp well surfaces were washed once with PBS 
and incubated with a 250 μL blocking buffer for 1.5 h. All li-
gands and SA-AP mixtures were diluted in the blocking buf-
fer. Ligand solutions (200 μL) were incubated in each well for 
2 h, removed, and the wells were washed six times with TBST, 
incubated for 1 h with SA-alkaline phosphatase, washed six 
times in TBST, and finally incubated with p-nitrophenylphos-
phate. The A405 values of the solutions were determined sev-
eral times within 1 h. Negative controls, used as blanks for the 
nonspecific binding of SA-alkaline phosphatase, were treated 
as above except for the addition of B-GAG.
Anti-HARE polyclonal antibody
The soluble ecto-domain of the 190-HARE protein (s190-
HARE) was purified by electro-elution, as described above, 
and used for Ab production by Pocono Rabbit Farm and Lab-
oratory, Inc. (www.prfal.com). Two rabbits were each ini-
tially injected with 0.2 mg s190-HARE in Freund’s complete 
adjuvant followed by three boosts with 0.1 mg s190-HARE in 
Freund’s incomplete adjuvant. IgG from the preimmune and 
postinjected rabbit serum was purified by protein A/G affinity 
chromatography according to the manufacturer’s instructions. 
The eluted total immune, but not preimmune, IgG recognized 
the soluble and membrane-bound forms of both 190 kDa and 
315 kDa HARE isoforms. Cell lysates separated by SDS–PAGE 
and probed with immune IgG by Western analysis revealed 
no cross-reactivity with other proteins (not shown).
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Endocytosis of 125I-SA-B-GAG complexes
Stably transfected cell lines were plated in 12-well dishes 
and grown in DMEM with 8% FBS containing 100 μg/mL Hy-
gromycin B for at least 2 days prior to experiments. Cells were 
washed with HBSS and incubated at 37°C for 60 min with the 
fresh endocytosis medium to clear any serum-derived GAGs 
bound to HARE. During this time, the 125I-SA-B-GAG com-
plexes were formed by incubating 1000 nM B-GAG and 480 
nM (25 μg/mL) 125I-SA in the endocytosis medium for 60 min 
at 22°C. Free biotin (1 μM) was then added to cap any unoc-
cupied biotin-binding sites in 125I-SA-B-GAG, and the pre-
formed complexes were then diluted 10-fold for most exper-
iments. Endocytosis assays were performed at 37°C in the 
endocytosis medium containing 125I-SA-B-GAG, with or with-
out an unlabeled GAG as a competitor. Nonspecific binding 
or endocytosis was assessed in two ways, in the presence of 
an excess of the same unlabeled GAG and with 125I-SA-biotin 
alone (no B-GAG) (Harris et al. 2007). At the indicated times, 
cells were washed three times with ice-cold HBSS, lysed in 0.3 
N NaOH, and radioactivity (using a gamma counter) and pro-
tein content (by the Bradford method) were determined. For 
the cross-competition experiments in Figure  2, we prepared 
125I-SA-B-HA and 125I-SA-B-Hep ligand complexes individu-
ally, by mixing 125I-SA with B-HA or B-Hep for 1 h, and then 
adding excess free biotin before mixing the two complexes to-
gether. This prevented SA, which has four biotin-binding sites, 
from forming dual complexes with both B-GAGs. The amount 
of 125I-SA was the same in all wells to equalize background 
CPM levels. Values for endocytosis are presented as the spe-
cific CPM/μg protein.
Western analyses
190-HARE or 190-HARE(ΔLink) cells were scraped from the 
flasks, washed three times by centrifugation with PBS, and 
lysed in PBS containing 0.5% Triton X-100 and protease inhib-
itors. Insoluble cellular debris was discarded after centrifuga-
tion at 1200 × g and protein content in the clarified lysates was 
quantified by the Bradford method (Bradford 1976). Cell lysate 
proteins were separated by 5% SDS–PAGE, electro-blotted to 
nitrocellulose (Burnette 1981), and probed with Ab to V5, an 
epitope common to all recombinant HARE proteins. Chemilu-
minescence was used to visualize bands, which were captured 
on Classic Blue BX film and quantified by densitometry using 
a FluoChem 8000 (Alpha Innotech).
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190-HARE the 190 kDa HA receptor for endocytosis
315-HARE the 315 kDa HA receptor for endocytosis. 
AcLDL acetylated low-density lipoprotein
BSA bovine serum albumin
CS chondroitin sulfate
DS dermatan sulfate
ECM extracellular matrix
EV empty vector
GAG glycosaminoglycan
HA hyaluronic acid, hyaluronate, hyaluronan
HARE HA Receptor for Endocytosis
HBSS Hanks’ balanced salts solution
Hep heparin
HS heparan sulfate
LDL low-density lipoprotein
PBS phosphate-buffered saline
s190-HARE soluble ecto-domain of the 190 kDa HARE
s315-HARE soluble ecto-domain of the 315 kDa HARE
SA streptavidin
TBST Tris-buffered saline containing Tween-20
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